References
- Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-318. https://doi.org/10.1097/00000658-199909000-00004
- Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996;77:1254-1262. https://doi.org/10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.0.CO;2-I
- Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995;19:59-71. https://doi.org/10.1007/BF00316981
- House MG, Ito H, Gonen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 2010;210:744-752, 752-755. https://doi.org/10.1016/j.jamcollsurg.2009.12.040
- Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677-3683. https://doi.org/10.1200/JCO.2008.20.5278
- Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008;247:125-135. https://doi.org/10.1097/SLA.0b013e31815aa2c2
- Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759-766. https://doi.org/10.1097/00000658-200206000-00002
- Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 2000;231:487-499. https://doi.org/10.1097/00000658-200004000-00006
- Ueno H, Mochizuki H, Hatsuse K, Hase K, Yamamoto T. Indicators for treatment strategies of colorectal liver metastases. Ann Surg 2000;231:59-66. https://doi.org/10.1097/00000658-200001000-00009
- Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. https://doi.org/10.1056/NEJMoa032691
- Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914. https://doi.org/10.1056/NEJM200009283431302
- de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
- Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
- Andres A, Toso C, Moldovan B, et al. Complications of elective liver resections in a Center With Low mortality: a simple score to predict morbidity. Arch Surg 2011 (in press).
- Kamiyama T, Nakanishi K, Yokoo H, et al. Perioperative management of hepatic resection toward zero mortality and morbidity: analysis of 793 consecutive cases in a single institution. J Am Coll Surg 2010;211:443-449. https://doi.org/10.1016/j.jamcollsurg.2010.06.005
- Huang ZQ, Xu LN, Yang T, et al. Hepatic resection: an analysis of the impact of operative and perioperative factors on morbidity and mortality rates in 2008 consecutive hepatectomy cases. Chin Med J (Engl) 2009;122:2268-2277.
- Pang YY. The Brisbane 2000 terminology of liver anatomy and resections. HPB 2000;2:333-339. https://doi.org/10.1016/S1365-182X(17)30755-4
- Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-213. https://doi.org/10.1097/01.sla.0000133083.54934.ae
- Eiber M, Fingerle AA, Brügel M, Gaa J, Rummeny EJ, Holzapfel K. Detection and classification of focal liver lesions in patients with colorectal cancer: Retrospective comparison of diffusionweighted MR imaging and multi-slice CT. Eur J Radiol 2011 (in press).
- Shinya S, Sasaki T, Nakagawa Y, Guiquing Z, Yamamoto F, Yamashita Y. The efficacy of diffusion-weighted imaging for the detection of colorectal cancer. Hepatogastroenterology 2009;56:128-132.
- O'Rourke TR, Welsh FK, Tekkis PP, et al. Accuracy of liver-specific magnetic resonance imaging as a predictor of chemotherapy-associated hepatic cellular injury prior to liver resection. Eur J Surg Oncol 2009;35:1085-1091. https://doi.org/10.1016/j.ejso.2009.01.015
- Blyth S, Blakeborough A, Peterson M, Cameron IC, Majeed AW. Sensitivity of magnetic resonance imaging in the detection of colorectal liver metastases. Ann R Coll Surg Engl 2008;90:25-28. https://doi.org/10.1308/003588408X242303
- Nomura K, Kadoya M, Ueda K, Fujinaga Y, Miwa S, Miyagawa S. Detection of hepatic metastases from colorectal carcinoma: comparison of histopathologic features of anatomically resected liver with results of preoperative imaging. J Clin Gastroenterol 2007;41:789-795. https://doi.org/10.1097/01.mcg.0000225676.22218.08
- Kuker RA, Mesoloras G, Gulec SA. Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease. Int Semin Surg Oncol 2007;4:17.
- Titu LV, Breen DJ, Nicholson AA, Hartley J, Monson JR. Is routine magnetic resonance imaging justified for the early detection of resectable liver metastases from colorectal cancer? Dis Colon Rectum 2006;49:810-815. https://doi.org/10.1007/s10350-006-0537-y
- Lowenthal D, Zeile M, Lim WY, et al. Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging. Eur Radiol 2011;21:832-840. https://doi.org/10.1007/s00330-010-1977-2
- Rappeport ED, Loft A. Liver metastases from colorectal cancer: imaging with superparamagnetic iron oxide (SPIO)-enhanced MR imaging, computed tomography and positron emission tomography. Abdom Imaging 2007;32:624-634. https://doi.org/10.1007/s00261-007-9297-y
- Vidiri A, Carpanese L, Annibale MD, et al. Evaluation of hepatic metastases from colorectal carcinoma with MR-superparamagnetic iron oxide. J Exp Clin Cancer Res 2004;23:53-60.
- Furuhata T, Okita K, Tsuruma T, et al. Efficacy of SPIO-MR imaging in the diagnosis of liver metastases from colorectal carcinomas. Dig Surg 2003;20:321-325. https://doi.org/10.1159/000071758
- Hagspiel KD, Neidl KF, Eichenberger AC, Weder W, Marincek B. Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. Radiology 1995;196:471-478.
- Wanebo HJ, Berz D. The neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors. J Surg Oncol 2010;102:891-897. https://doi.org/10.1002/jso.21691
- Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP, Prasad KR. Interaction of tumour biology and tumour burden in determining outcome after hepatic resection for colorectal metastases. HPB (Oxford) 2010;12:84-93. https://doi.org/10.1111/j.1477-2574.2009.00127.x
- Yasui K, Hirai T, Kato T, et al. A new macroscopic classification predicts prognosis for patient with liver metastases from colorectal cancer. Ann Surg 1997;226:582-586. https://doi.org/10.1097/00000658-199711000-00002
- Karanjia ND, Lordan JT, Quiney N, Fawcett WJ, Worthington TR, Remington J. A comparison of right and extended right hepatectomy with all other hepatic resections for colorectal liver metastases: a ten-year study. Eur J Surg Oncol 2009;35:65-70. https://doi.org/10.1016/j.ejso.2007.12.002
- Ferrero A, Vigan L, Lo Tesoriere R, Russolillo N, Sgotto E, Capussotti L. Bisegmentectomies as alternative to right hepatectomy in the treatment of colorectal liver metastases. Hepatogastroenterology 2009;56:1429-1435.
- Torzilli G, Donadon M, Marconi M, et al. Systematic extended right posterior sectionectomy: a safe and effective alternative to right hepatectomy. Ann Surg 2008;247:603-611. https://doi.org/10.1097/SLA.0b013e31816387d7
- Gold JS, Are C, Kornprat P, et al. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann Surg 2008;247:109-117. https://doi.org/10.1097/SLA.0b013e3181557e47
- Elias D, Baton O, Sideris L, et al. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol 2005;90:36-42. https://doi.org/10.1002/jso.20237
- Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011;22:2042-2048. https://doi.org/10.1093/annonc/mdq714
- Karasaki T, Sano K, Takamoto T, et al. Complete resection of unresectable liver metastases from colorectal cancer without deterioration of liver function after cetuximab and irinotecan: two case reports. Hepatogastroenterology 2010;57:1526-1528.
- Garufi C, Torsello A, Tumolo S, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010;103:1542-1547. https://doi.org/10.1038/sj.bjc.6605940
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247. https://doi.org/10.1016/j.ejca.2008.10.026
- Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-1016. https://doi.org/10.1016/S0140-6736(08)60455-9